International pharmaceutical company Life Molecular Imaging (LMI) and SOFIE Biosciences, a US manufacturer and developer of PET radiopharmaceuticals, announced on Tuesday an expansion of their strategic partnership and licensing agreement to provide and distribute Neuraceq from SOFIE's radiopharmaceutical manufacturing site near Albany, New York.

This agreement will increase availability of Neuraceq for imaging centres, physicians, and patients with cognitive impairment around New York, Massachusetts and Vermont, with the first doses made available on 19 May 2025.

Neuraceq is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment such as Alzheimer's disease.

Colleen Ruby, US country head and chief operating officer, Americas and APAC, said: "At LMI, we are committed to broadening access to Neuraceq availability for patients and physicians navigating the evaluation of Alzheimer's disease, especially as new treatment options emerge. By expanding our manufacturing capabilities in Albany, NY, through our partnership with SOFIE, we're better positioned to meet the increasing demand for amyloid PET imaging."